MCAM and neoplasm: Using a subcutaneous Matrigel plug tumor model, we found that either imaprelimab (an antibody for CD146) or bemcentinib (R428) effectively inhibited subcutaneous tumor growth; furthermore, they showed a significantly increased effect compared with Bev, manifested by stronger suppression of subcutaneous tumor growth (Figure 7A-C).